| THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL Patent applications |
| Patent application number | Title | Published |
|---|
| 20120114554 | Engineered Aerosol Particles, And Associated Methods - An engineered aerosol particle for use in aerosol applications is provided. The engineered aerosol particle comprises a fabricated nanoparticle body member being non-spherical. The fabricated nanoparticle body member is configured to provide at least one of auto-rotation, tumbling, or lift when entrained in an airstream to thereby increase settling time of the fabricated nanoparticle body member. An associated method is also provided. | 05-10-2012 |
| 20120064075 | CHIMERIC FACTOR VII MOLECULES WITH ENHANCED HALF LIFE AND METHODS OF USE - The present invention relates to novel proteins and methods of using chimeric Factor VIIa polypeptides. | 03-15-2012 |
| 20120034169 | NITRIC OXIDE-RELEASING PARTICLES FOR NITRIC OXIDE THERAPEUTICS AND BIOMEDICAL APPLICATIONS - The presently disclosed subject matter relates to nitric oxide-releasing particles for delivering nitric oxide, and their use in biomedical and pharmaceutical applications. | 02-09-2012 |
| 20120021055 | NITRIC OXIDE-RELEASING PARTICLES FOR NITRIC OXIDE THERAPEUTICS AND BIOMEDICAL APPLICATIONS - The presently disclosed subject matter relates to nitric oxide-releasing particles for delivering nitric oxide, and their use in biomedical and pharmaceutical applications. | 01-26-2012 |
| 20120009268 | Modified Virus Vectors and Methods of Making and Using the Same - The present invention provides AAV capsid proteins (VP1, VP2 and/or VP3) comprising a modification in the amino acid sequence in the three-fold axis loop 4 and virus capsids and virus vectors comprising the modified AAV capsid protein. In particular embodiments, the modification comprises a substitution of one or more amino acids at amino acid positions 585 to 590 (inclusive) of the native AAV2 capsid protein sequence or the corresponding positions of other AAV capsid proteins. The invention also provides methods of administering the virus vectors and virus capsids of the invention to a cell or to a subject in vivo. | 01-12-2012 |
| 20110306878 | INTERVENTIONAL DRUG DELIVERY SYSTEM AND ASSOCIATED METHODS - A delivery system for local drug delivery to a target site of internal body tissue is provided. The delivery system comprises a source electrode adapted to be positioned proximate to a target site of internal body tissue. A counter electrode is in electrical communication with the source electrode, and is configured to cooperate with the source electrode to form a localized electric field proximate to the target site. A reservoir is configured to be disposed such that the reservoir is capable of interacting with the localized electric field. The reservoir is configured to carry a cargo capable of being delivered to the target site when exposed to the localized electric field. Associated methods are also provided. | 12-15-2011 |
| 20110301228 | GENE THERAPY VECTOR FOR TREATMENT OF STEROID GLAUCOMA - The presently disclosed subject matter provides an inducible vector comprising a therapeutic gene. In some embodiments a method is provided for treating steroid glaucoma. In some embodiments a method is provided for preventing elevated intraocular pressure in a subject receiving steroid treatment. In some embodiments a method is provided for reversing elevated intraocular pressure in a subject receiving steroid treatment. In some embodiments a steroid treatment method is provided. Also provided are pharmaceutical compositions comprising an inducible vector. | 12-08-2011 |
| 20110284805 | PRODUCTION OF MECHANICALLY EXFOLIATED GRAPHENE AND NANOPARTICLE COMPOSITES COMPRISING SAME - A method for producing nanospacer-graphene composite materials (i.e., mechanically-exfolitated graphene), wherein the graphene sheets are interspersed with nanospacers, thereby maintaining the 2D characteristics of the graphene sheets. The nanospacer-graphene composite material is highly porous, has a high surface area and is highly electrically conductive and may be optically transparent. | 11-24-2011 |
| 20110264030 | DELIVERY APPARATUS AND ASSOCIATED METHOD - A delivery apparatus for delivering a cargo to a target site of internal body tissue is provided. The delivery apparatus comprises a flexible tubular member having a distal end adapted for insertion proximate to the target site. A first electrode is configured for insertion within the flexible tubular member such that the first electrode is capable of being disposed proximate to the target site. A second electrode is configured to cooperate with the first electrode to form an electric field. A delivery component has a cargo carried thereby and is coupled with the first electrode. The delivery component is configured to degrade when exposed to the electric field such that the cargo is released to the target site upon degradation thereof. An associated method is also provided. | 10-27-2011 |
| 20110195030 | NANOPARTICLE COMPOSITIONS COMPRISING LIQUID OIL CORES - Nanocapsule and nanoemulsion particle compositions having improved physical and pharmacological properties are provided. The nanocapsule or nanoemulsion particle composition can comprise a pharmaceutically acceptable liquid oil phase, a surfactant, and optionally a co-surfactant. The liquid oil phase can comprise a monoglyceride, a diglyceride, a triglyceride, a propylene glycol ester, or a propylene glycol diester. In certain embodiments, the nanocapsule or nanoemulsion particle composition can be lyophilized and subsequently re-hydrated without increasing the mean particle size and/or adversely affecting the potency or efficacy of a therapeutic agent (e.g., paclitaxel) present in the nanocapsules or nanoemulsion particles. | 08-11-2011 |
| 20110186789 | SYNTHESIS OF GRAPHENE SHEETS AND NANOPARTICLE COMPOSITES COMPRISING SAME - A method for producing isolatable and dispersible graphene sheets, wherein the graphene sheets may be tailored to be soluble in aqueous, non-aqueous or semi-aqueous solutions. The water soluble graphene sheets may be used to produce a metal nanoparticle-graphene composite having a specific surface area that is 20 times greater than aggregated graphene sheets. Graphene sheets that are soluble in organic solvents may be used to make graphene-polymer composites. | 08-04-2011 |
| 20110172295 | METHODS AND COMPOSITIONS FOR THE REGULATION OF microRNA PROCESSING - Provided herein are methods and compositions for the regulation of microRNA processing. The invention presents methods for inhibiting the activity of a Lin-28-like polypeptide and methods for treating a subject with cancer comprising administering to a subject with cancer a compound that inhibits the activity of a Lin-28-like polypeptide. Compositions comprise isolated polynucleotides and expression cassettes comprising the same that promote the processing of at least one of a regulated primary microRNA transcript by Drosha and a regulated precursor microRNA by Dicer when introduced into or expressed in a cell. Compositions and methods are also provided for the selective suppression of target polynucleotides by a microRNA based on the level of expression of a Lin-28-like polypeptide within a cell. | 07-14-2011 |
| 20110165141 | Compositions for treating bacterial infections - Polynucleotides encoding a mutant human carboxylesterase enzyme and polypeptides encoded by the polynucleotides which are capable of metabolizing a prodrug and inactive metabolites thereof to active drug are provided. Compositions and methods for sensitizing cells to a prodrug agent, inhibiting cell growth, treating drug addiction, and facilitating the metabolism of an organophosphate with this enzyme are also provided. In addition, a screening assay for identification of drugs activated by this enzyme is described. | 07-07-2011 |
| 20110152229 | BETULINIC ACID DERIVATIVES AS ANTI-HIV AGENTS - The present invention provides compounds of the general structure: | 06-23-2011 |
| 20110123446 | DEGRADABLE COMPOUNDS AND METHODS OF USE THEREOF, PARTICULARLY WITH PARTICLE REPLICATION IN NON-WETTING TEMPLATES - The present invention provides compounds that will degrade under specified conditions, methods of using such compounds, and compositions comprising such compounds. The degradable compounds of the invention may be characterized by the labile —Si-A-C— groups present in the compounds (A representing an atom, such as O, N, or S, or a group, such as C═O). The compounds may be incorporated into a composition that further may include a polymeric matrix and/or a cargo component. A wide variety of cargo components may also be used in the present invention. In particular embodiments, the cargo component comprises a drug or other therapeutic agent. Accordingly, the invention particularly provides pharmaceutical formulations and methods of delivering a drug or other therapeutic material. | 05-26-2011 |
| 20110104139 | ANGIOSTATIC COMPOSITIONS COMPRISING TRUNCATED TYROSYL-tRNA SYNTHETASE POLYPEPTIDES AND METHODS OF USING SAME - Angiostatic compositions are provided comprising truncated forms of tyrosyl tRNA synthetase polypeptides. Also provided are methods of using such compositions in the treatment of conditions that benefit from decreased angiogenesis and/or neovascularization. | 05-05-2011 |
| 20110027806 | FARNESYLTRANSFERASE INHIBITORS FOR TREATMENT OF LAMINOPATHIES, CELLULAR AGING AND ATHEROSCLEROSIS - Although it can be farnesylated, the mutant lamin A protein expressed in Hutchinson Gilford Progeria Syndrome (HGPS) cannot be defarnesylated because the characteristic mutation causes deletion of a cleavage site necessary for binding the protease ZMPSTE24 and effecting defarnesylation. The result is an aberrant farnesylated protein (called “progerin”) that alters normal lamin A function as a dominant negative, as well as assuming its own aberrant function through its association with the nuclear membrane. The retention of farnesylation, and potentially other abnormal properties of progerin and other abnormal lamin gene protein products, produces disease. Farnesyltransferase inhibitors (FTIs) (both direct effectors and indirect inhibitors) will inhibit the formation of progerin, cause a decrease in lamin A protein, and/or an increase prelamin A protein. Decreasing the amount of aberrant protein improves cellular effects caused by and progerin expression. Similarly, treatment with FTIs should improve disease status in progeria and other laminopathies. In addition, elements of atherosclerosis and aging in non-laminopathy individuals will improve after treatment with farnesyltransferase inhibitors. | 02-03-2011 |
| 20100286280 | INHIBITORS OF EPPIN/SEMENOGELIN BINDING AS MALE CONTRACEPTIVES - Compounds suitable for use in providing male contraception, an assay method for identifying such compounds, and methods of providing contraception using the compounds, are provided. The compounds described herein inhibit Eppin-semenogelin binding, and inhibit forward motility of sperm in humans and other primates. The assays identify compounds which both inhibit eppin-semenogelin binding and inhibit sperm motility, and can be carried out in a high throughput manner, using labeled recombinant Eppin and semenogelin. The compounds can be used in oral or transdermal compositions to temporarily and reversibly inhibit male fertility. They can also be used in addition to, or in place of, spermicides in spermicidal compositions, such as those used in conjunction with condoms, diaphragms, and spermicidal jellies. | 11-11-2010 |
| 20100272712 | JNK3 AS A TARGET FOR THE TREATMENT OF ANGIOGENESIS-RELATED DISEASES - Provided herein are methods for treating a subject having or at risk for an angiogenesis-related disorder. The methods include administering to the subject a therapeutically effective amount of an agent that inhibits JNK3 expression, or a therapeutically effective amount of an agent that inhibits JNK3 activity. Disorders that can be treated by these methods include cancer, rheumatoid arthritis, vascular diseases, and other disorders resulting from excessive angiogenesis. The therapeutic agent may be a compound, small molecule, peptide, antibody, antisense nucleic acid, ribozyme, or the like. Methods of identifying a candidate agent that modulates JNK3 expression are also provided. | 10-28-2010 |
| 20100196277 | NANOPARTICLE COMPOSITIONS FOR CONTROLLED DELIVERY OF NUCLEIC ACIDS - Micro- and nano-particles are molded in micro- and nano-scale molds fabricated from non-wetting, low surface energy polymeric materials. The micro- and nano-particles can include pharmaceutical compositions, biologic drugs, drug compositions, organic materials, RNA, DNA, oligonucleotides, and the like. | 08-05-2010 |
| 20100196256 | TITANIA NANOSHEETS DERIVED FROM ANATASE DELAMINATION - A novel titania nanosheet material synthesized using a novel mechanism using titania nanotubes as a starting material is described. The novel nanosheet material may be useful for many coating applications where titania nanoparticles are traditionally deposited including, but not limited to, self-cleaning coatings, gas sensors, hydrogen production, photocatalytic solar cells, and batteries. | 08-05-2010 |
| 20100190703 | PEPTIDES SPECIFIC FOR HUMAN BLOOD OUTGROWTH ENDOTHELIAL CELLS - Provided herein are compositions and methods for binding outgrowth endothelial cells (OEC). The compositions consist of peptide ligands capable of binding OEC with high affinity and specificity. The compositions of the invention include peptides set forth in SEQ ID NO: 1-38 and variants and derivatives thereof. Compositions also include the nucleotide sequences encoding the peptides of the invention. The compositions find use in methods for the isolation of OEC and for the recruitment and retention of OEC to sites of therapeutic interest. Methods for the identification and isolation of other peptides capable of binding OEC are also provided. | 07-29-2010 |
| 20100178278 | FORMABLE BIOCERAMICS - A formable bioceramic including hydroxyapatite nanocrystals, gelatin, and sol-gel-containing material is described. Also described is a process for making and using the bioceramic. The formable bioceramic displays superior mechanical strength, elasticity, biocompatibility and forming capabilities and is targeted for bone repairs and template-assisted tissue engineering applications. | 07-15-2010 |
| 20100150930 | MAGE-11 AS A MARKER FOR ENDOMETRIAL RECEPTIVITY TO EMBRYO TRANSPLANTATION AND A MARKER AND THERAPEUTIC TARGET IN CASTRATION-RECURRENT PROSTATE CANCER - Compositions and methods for determining endometrial receptivity to embryo implantation and for detecting and treating castration-recurrent prostate cancer are provided. The methods comprise measuring the level of melanoma antigen gene protein-11 (MAGE-11, also referred to as MAGE-Al 1) in an endometrial or prostate tissue sample. The level of MAGE-11 protein or mRNA can be correlated to endometrial receptivity to embryo implantation in a female human or nonhuman primate, or to the presence of castration-recurrent prostate cancer in a male patient in need thereof. Methods are described whereby MAGE-11 may serve as a target for vaccine development in the treatment of castration-recurrent prostate cancer. Methods for monitoring endometrial maturation, for diagnosing infertility, and for in vitro fertilization in a female human or nonhuman primate are also provided. Compositions of the invention include antibodies that specifically bind MAGE-11 and oligonucleotide primers useful for detecting MAGE-11 mRNA, as well as kits containing such antibodies or primers. | 06-17-2010 |
| 20100147365 | HIGH FIDELITY NANO-STRUCTURES AND ARRAYS FOR PHOTOVOLTAICS AND METHODS OF MAKING THE SAME - A photovoltaic device includes an electron accepting material and an electron donating material. One of the electron accepting or donating materials is configured and dimensioned as a first component of a bulk heterojunction with a predetermined array of first structures, each first structure is substantially equivalent in three dimensional shape, has a substantially equivalent cross-sectional dimension, and where each first structure of the array of first structures has a substantially equivalent orientation with respect to adjacent first structures of the predetermined array forming a substantially uniform array. | 06-17-2010 |
| 20100101308 | METHODS AND SYSTEMS FOR MULTIFORCE HIGH THROUGHPUT SCREENING - Methods and systems for multiforce high throughput screening are disclosed. According to one aspect, the subject matter includes a high throughput screening system that includes a multiforce plate having a plurality of field forming poles where each field forming pole is positioned on the multiforce plate at a location corresponding to a well in a multiwell plate. The system also includes an exciter assembly with excitation poles positioned at locations corresponding to the field forming poles. The excitation poles are utilized for electrically or magnetically coupling to the field forming poles and for delivering at least one of an electric and magnetic field in the vicinity of the field forming poles. The coupled field forming poles apply force via the field(s) to probes located in the wells of the multiforce plate in order to move the probes and test mechanical properties of specimens in the wells. | 04-29-2010 |
| 20100057490 | METHODS, SYSTEMS, AND COMPUTER PROGRAM PRODUCTS FOR EVALUATING A PATIENT IN A PEDIATRIC INTENSIVE CARE UNIT - Methods, systems, and computer program products for evaluating a patient in a pediatric intensive care unit (PICU) are disclosed. According to one aspect, a method may include collecting physiological data associated with a patient upon admission to a PICU and at least once after admission to the PICU. The physiological data may be associated with a statistical model, and a risk of mortality of the patient may be continually determined. | 03-04-2010 |
| 20100051480 | NITRIC OXIDE MICROSENSORS VIA FLUOROSILANE-BASED XEROGEL MEMBRANES - The presently disclosed subject matter relates to sensors for measuring an amount of a gaseous species in a sample. The sensors comprise a gas permeable polysiloxane network membrane, comprising both alkyl and fluorinated alkyl groups. In some embodiments, the polysiloxane network can be formed from the co-condensation of a mixture of an alkylalkoxysilane and a fluorosilane. The presently disclosed subject matter also relates to methods of making the sensors, methods of selectively measuring an amount of a gaseous species, such as nitric oxide, in a sample, and to compositions comprising the polysiloxane networks. | 03-04-2010 |
| 20090299640 | Methods and Compositions Involving Intrinsic Genes - Disclosed are compositions and methods related intrinsic gene sets and methods and compositions related to detecting and classifying cancer. | 12-03-2009 |
| 20090281250 | METHODS AND MATERIALS FOR FABRICATING MICROFLUIDIC DEVICES - Materials and Methods are provided for fabricating microfluidic devices. The materials include low surface energy fluoropolymer compositions having multiple cure functional groups. The materials can include multiple photocurable and/or thermal-curable functional groups such that laminate devices can be fabricated. The materials also substantially do not swell in the presence of hydrocarbon solvents. | 11-12-2009 |
| 20090220789 | TAGGANTS AND METHODS AND SYSTEMS FOR FABRICATING SAME - A micro or nanoparticle ( | 09-03-2009 |
| 20090216079 | Capsule Imaging Devices, Systems and Methods for in Vivo Imaging Applications - Novel capsule imaging devices, systems and methods are provided for in vivo imaging applications, such as for gastrointestinal applications. A swallowable video imaging device, such as a capsule, can be used with a light filter for in vivo illumination of a target tissue that has absorbed a previously administered biological probe. The target tissue can be distinguished in images transmitted from the video imaging device. Quantification of the signal intensity of fluorescence can be used to assess how progressed the target tissue may be. The target tissue can be therapeutically treated to shrink or kill the target tissue. | 08-27-2009 |
| 20090023038 | LIQUID MATERIALS FOR USE IN ELECTROCHEMICAL CELLS - Disclosed is the use of liquid precursor materials to prepare a processible polymeric electrolyte, which can be used to form a proton exchange membrane for use in an electrochemical cell. Also disclosed is the use of liquid precursor materials to prepare a processible catalyst ink composition, which can be conformally applied to a proton exchange membrane and a electrode material for use in an electrochemical cell. Also disclosed is the use of a photocurable perfluoropolyether (PFPE) material to form a microfluidic electrochemical cell. | 01-22-2009 |
| 20080293133 | Textiles for use in bioreactors for expansion and maintenance of cells - A bioreactor for three-dimensional culture of liver cells is disclosed. The device is characterized by the use of textile vasculatures. A model and method for optimizing vasculature parameters is also disclosed. Liver acinar structure and physiological parameters are mimicked by sandwiching cells in the space between the two innermost woven textile hollow fibers, and creating radial flow of media from an outer compartment, through the cell mass compartment, and to an inner compartment. The theoretical optimum hydraulic permeability for the two innermost semi-permeable membranes is determined based on physiological hepatic sinusoidal blood flow and pressures. Experimental studies using a flow rate and pressure monitoring systems in conjunction with phase-contrast velocity-encoded MRI confirm theoretical results. Novel woven vascular tubes with optimum hydraulic permeability are disclosed for culturing hepatocytes in the multi-coaxial bioreactor. | 11-27-2008 |
| 20080234752 | Surgical plate puller devices and methods for use with surgical bone screw/plate systems - A plate puller device can include a head portion and extension rod portion. The device enables the fastener receiving member to be pulled against a bone surface before a head section of the fastener is advanced within the fastener receiving member into a locked position. The head portion can be positioned between the head section of the fastener and a surface of the fastener receiving member not adjacent to the bone surface. Also, a plate puller device can include a screwdriver, a grasper portion and a grasper sleeve. The grasper portion and grasper sleeve can be threadingly mated wherein rotation of the grasper sleeve forces a head portion of the grasper portion to grip the head section of the fastener to prevent the head section from advancing within the fastener receiving member. | 09-25-2008 |
| 20080233572 | METHODS AND COMPOSITIONS FOR THE DETECTION AND QUANTIFICATION OF E.COLI AND ENTEROCOCCUS - The present invention is drawn to methods and compositions for the rapid assessment of fecal indicator bacteria in a sample. Provided herein are novel primer and probe compositions for use in detecting the presence of these organisms in a sample, particularly using quantitative PCR methods. Provided herein are novel oligonucleotide primers and probes, including the primers set forth in SEQ ID NO:1-4, the novel oligonucleotide probe sequences set forth in SEQ ID NO:5-8, and methods for using these primers and probes for the detection and/or quantification of fecal indicator bacteria, particularly | 09-25-2008 |
